Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B82—NANOTECHNOLOGY
  • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
  • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/34—Alcohols
  • A61K8/342—Alcohols having more than seven atoms in an unbroken chain
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/37—Esters of carboxylic acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/37—Esters of carboxylic acids
  • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
  • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/10—Anti-acne agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/10—Antimycotics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q15/00—Anti-perspirants or body deodorants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
  • A61Q17/005—Antimicrobial preparations
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
  • A61Q1/02—Preparations containing skin colorants, e.g. pigments
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/10—Washing or bathing preparations

Definitions

• the invention relates to the use of specific fatty substances allowing to modify the physico-chemical properties of the surface of the skin and / or mucous membranes in a cosmetic composition or for the preparation of a pharmaceutical composition as agents preventing or reducing the adhesion of microorganisms, particularly bacteria, on the skin and / or mucous membranes.
• the resident microbial flora essential for good skin health, consists mainly of staphylococci ( Staphylococcus epidermis and Staphylococcus hominis ), corynebacteria, Gram + propionibacteria such as Propionibacterium acnes , as well as a fungal flora mainly composed of Pytosporum ovale .
• Skin infections are most often due to the disruption of the ecological balance of the resident flora following the colonization of the skin by pathogenic exogenous germs or the abnormal proliferation of an endogenous strain.
• the best known pathogens are Pseudomonas aeruginosa (Gram -) which is responsible for small pimples, folliculitis, redness and pruritus, Candida albicans which can cause inflammation at the commissure of the lips, cutaneous candidiasis, pruritus, folliculitis and canker sores, Staphylococcus aureus which can cause pimples, folliculitis, impetigo, and boils, and group A Streptococcus responsible for impetigo.
• Pseudomonas aeruginosa Gram -
• Candida albicans which can cause inflammation at the commissure of the lips
• cutaneous candidiasis, pruritus, folliculitis and canker sores Sta
• antibiotics or bactericides To combat these microorganisms, it is common to use antibiotics or bactericides. The use of these compounds however poses the problem of the non-specificity of action indifferently targeting the flora pathogen and the resident flora, the problem of the risk of occurrence of bacterial resistance, as well as skin tolerance problems (irritations, allergies, ).
• the Applicant has surprisingly found that bodies specific fats, free of carbohydrate units, allowed significantly reduce microbial adhesion to the skin and / or mucous membranes and thereby prevent the proliferation of potentially germs pathogens in the absence of antibiotic, bactericidal or fungicidal agents.
• fatty substances unlike the carbohydrates that bind to receptors for microorganisms to prevent binding to corneocyte glycolipids, act on the physicochemical properties of the surface of the skin and / or mucous membranes, these physicochemical properties involving the electrodynamic interactions due to Van der Waals forces, the acid-base interactions according to Lewis and the electrostatic interactions.
• these fatty substances are not bactericidal. Therefore, they do not do not cause unwanted side effects on the skin and / or mucous membranes.
• the fatty substances according to the invention used as principles active, reduce or prevent adhesion of a microorganism whose overall surface charge is negative or positive by increasing the respectively negative or positive charge of the skin, so as to cause repulsion between the skin and / or mucous membranes and the micro-organism.
• the fatty substances according to the invention used as principles active, furthermore make it possible to reduce or prevent the adhesion of a microorganism, by limiting Van der type interactions as much as possible Waals between the skin and / or mucous membranes and the micro-organism, favoring repulsive acid-base interactions according to Lewis and limiting the attractive Lewis-acid-base interactions between the microorganism and the skin and / or mucous membranes.
• the subject of the invention is therefore the use as an active principle, in a cosmetic composition or for the preparation of a composition pharmaceutical, of an effective amount of at least one fatty substance free of carbohydrate units, with a melting point below 35 ° C and having an interfacial tension between 6 and 27 mN / m, modifying the physicochemical properties of the surface of the skin and / or mucous membranes, with a view to preventing or reducing the adhesion of microorganisms to these past.
• the fatty substance or the composition containing it can be used both preventively, for its ability to prevent, totally or partially, the adhesion of microorganisms, only as a curative for its ability to facilitate the detachment of microorganisms.
• these fatty substances are such that the decimal logarithm of the average number of viable bacteria adhering to the reconstructed epidermis, after a test for bringing said epidermis into contact with the compound tested for 2 hours at 37 ° C, is at least 0.3 less, preferably 0.5 and more preferably 1, to that obtained by a test carried out with water in the same conditions.
• the reconstructed epidermis used in the test indicated above is the reconstituted human epidermis, equivalent to human skin, sold by the EPISKIN company.
• This test assesses changes in physico-chemical properties surface of the skin and / or mucous membranes, involving Van der Waals electrodynamic interactions, acid-base interactions according to Lewis and electrostatic interactions.
• sesame oil octoxyglyceryl palmitate, octoxyglyceryl behenate, dioctyl adipate, apricot almond oil, tartrate of branched C 12 -C 13 di-alcohols and / or mixtures thereof
• the fatty substance or the composition is used. containing topical application to the skin and / or mucous membranes.
• One aspect of the invention is therefore to propose the use of a fatty substance free of carbohydrate units, of melting temperature below 35 ° C and having an interfacial tension between 6 and 27 mN / m, as an active principle in a cosmetic composition or for the preparation of a pharmaceutical composition.
• the invention relates to cosmetic use in topical application of at least one fatty substance, as defined above, in as an active ingredient in a cosmetic composition intended to reduce bad body odors and / or intended for hygiene care bodily.
• personal hygiene care any substance or preparations intended to be put in contact with the various parties surface of the human body and / or with teeth and / or mucous membranes in order to clean them, protect them, keep them in good condition, modify the appearance, perfume them or correct their odor.
• the invention relates to cosmetic use in topical application of at least one fatty substance free of hydrate units carbon, with a melting temperature below 35 ° C and having a tension interfacial between 6 and 27 mN / m, as an active ingredient in a cosmetic composition to fight against blackheads and / or dandruff.
• the microbial flora of the skin surface is responsible for a large number of disorders.
• the subject of the invention is also the use of a body fat free of carbohydrate units, of melting point below 35 ° C and having an interfacial tension between 6 and 27 mN / m, as active ingredient for the preparation of a composition pharmaceutical intended to be used in topical application to fight against fungal infections and / or acne, particularly juvenile acne.
• the amount of fatty substance that can be used according to the invention depends well obviously of the desired effect and must be an effective amount for partially or completely prevent adhesion of microorganisms or to facilitate the detachment of microorganisms.
• the quantity of fatty substance that can be used according to the invention can range, for example, from 0.1 to 100% and preferably from 0.5 to 50% and better from 5 to 25% of the total weight of the composition.
• the invention also relates to a cosmetic process for treat disorders associated with the adhesion of microorganisms consisting of applying to the skin a cosmetic composition comprising at least one fatty substance according to the invention in a cosmetically acceptable medium.
• cosmetically acceptable medium is meant a medium compatible with the skin, scalp, mucous membranes, nails, and hair.
• compositions used according to the invention can be presented in all dosage forms normally used for topical application, especially under form of anhydrous, liquid, pasty or solid products such as lotions oily, oily gels, ointments, or in the form of oil-in-water emulsions or water-in-oil or multiple, or a dispersion of oil in a aqueous phase using spherules, these spherules can be polymeric nanoparticles such as nanospheres and nanocapsules, or better, lipid vesicles of ionic and / or nonionic type.
• compositions of the invention are more pleasant to use, softer on application, more nourishing and more emollient, it is possible to add an additional fatty phase in the middle of these compositions while ensuring the non-stick efficacy of the mixture.
• the additional fatty phase preferably represents from 0 to 50 % by total weight of the composition.
• fatty acids or waxes paraffin, polyethylene wax, Carnauba, beeswax.
• compositions used in the invention may also contain adjuvants customary in the field cosmetics such as solvents, gelling agents and / or thickeners hydrophilic or lipophilic classics; hydrophilic or lipophilic active agents; preservatives; antioxidants; perfumes; emulsifiers; of moisturizers; pigmenting agents; depigmenters; agents keratolytics; vitamins; emollients; sequestrants; surfactants; polymers; basifying or acidifying agents; charges; anti-free radical agents; ceramides; sun filters (especially ultra-violet); insect repellents; agents slimming; coloring matters; anti-dandruff.
• adjuvants customary in the field cosmetics such as solvents, gelling agents and / or thickeners hydrophilic or lipophilic classics; hydrophilic or lipophilic active agents; preservatives; antioxidants; perfumes; emulsifiers; of moisturizers; pigmenting agents; depigmenters; agents keratolytics;
• surfactants such as polydimethicone copolyols and alkyldimethicone copolyols such as the product sold under the name Abil EM90 by the company Goldschmidt; esters of fatty acids and polyols such that PEG-7 glyceryl cocoate as the product sold by the company COGNIS under the name Cetiol HE.
• hydrophilic organic solvents and for example lower mono-alcohols, linear or branched, having from 1 with 8 carbon atoms like ethanol, propanol, butanol, isopropanol, isobutanol; polyethylene glycols having 6 to 80 oxides ethylene; polyols such as propylene glycol, isoprene glycol, butylene glycol, glycerol; isosorbide mono- or dialkyls whose alkyl groups have from 1 to 5 carbon atoms such as dimethyl isosorbide; glycol ethers like diethylene glycol mono-methyl or mono-ethyl ether and propylene glycol ethers such as dipropylene methyl ether glycol.
• compositions used in the present invention can be more or less fluid and have the appearance of a white or colored cream, a ointment, milk, lotion, serum, paste, foam or of a solid.
• They can optionally be applied to the skin in the form aerosol.
• They can also be in solid form, and by example in the form of a stick.
• They can be used as a care product, as a product skin or hair cleanser, as sunscreen, as make-up product such as foundations, lipsticks, mascaras, eyeshadows, and / or as a simple deodorant product.
• the subject of the invention is therefore a cosmetic care composition, cleaning, make-up or deodorant comprising at least one body fat according to the invention.
• the anti-adhesion test meets the protocol below:
• the reconstructed epidermis Before bacterial adhesion, the reconstructed epidermis is brought into contact for 2 hours with 25 mg of the fatty substance to be tested at 37 ° C. Then added 1 ml of bacterial suspension of Staphylococcus aureus at a concentration of 10 7 germs / ml in Tryptone salt. After incubation for 24 hours at 37 ° C, the bacterial suspension is emptied and five rinses are carried out with 1 ml of sterile distilled water. The reconstructed epidermis detached from its support is then ground using a robot in 18 ml of Tryptone salt.
• This suspension is decimal diluted in Tryptone salt, then 1 ml of the dilution is seeded in 15 ml of Trypticase Soy agar and incubated for 24 hours at 37 ° C. Then there are the adherent and viable cells.
• This anti-adhesion test makes it possible to evaluate the effectiveness of molecules alone or finished products.
• a bacteria / product mixture to be tested in the same ratio as in the anti-adhesion test, is brought into contact for 24 hours at 37 ° C.
• the test can require shaking incubation to avoid bacteria death by lack of oxygen, for certain fatty substances.
• Counting germs is carried out by decimal dilution in Tryptone salt and seeding with 100 ⁇ l rake on Trypticase Soy Agar. Counting colonies takes place after 24 hours of incubation at 37 ° C.
• the viability test carried out prior to the anti-adhesion test eliminates any bactericidal component of molecules or products finished tested and highlight only the anti-adhesion activity.
• the figures presented opposite the fatty substance correspond to the reduction in the decimal logarithm of the average number of viable Staphylococcus aureus adhering to the epidermis reconstructed after treatment with the fatty substance under the conditions defined by the previous test compared to the decimal logarithm of the average number of viable Staphylococcus aureus adhering to the reconstructed epidermis after treatment with water under the same conditions.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Epidemiology (AREA)
• Birds (AREA)
• Dermatology (AREA)
• Emergency Medicine (AREA)
• Engineering & Computer Science (AREA)
• Pharmacology & Pharmacy (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Medicinal Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nanotechnology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Crystallography & Structural Chemistry (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• General Physics & Mathematics (AREA)
• Biochemistry (AREA)
• Physics & Mathematics (AREA)
• Immunology (AREA)
• Pathology (AREA)
• Communicable Diseases (AREA)
• Manufacturing & Machinery (AREA)
• Oncology (AREA)
• Analytical Chemistry (AREA)
• Cosmetics (AREA)
• Medicinal Preparation (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Edible Oils And Fats (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)

Applications Claiming Priority (2)

Publications (3)

Family

ID=8847001

Family Applications (1)

Country Status (9)

Cited By (12)

Families Citing this family (3)

Citations (19)

Family Cites Families (8)

• 2000
  • 2000-02-15 FR FR0001842A patent/FR2804865B1/fr not_active Expired - Lifetime
• 2001
  • 2001-02-08 DE DE60114272T patent/DE60114272T2/de not_active Expired - Lifetime
  • 2001-02-08 ES ES01400307T patent/ES2247030T3/es not_active Expired - Lifetime
  • 2001-02-08 EP EP01400307A patent/EP1133979B1/de not_active Revoked
  • 2001-02-08 AT AT01400307T patent/ATE307561T1/de not_active IP Right Cessation
  • 2001-02-13 KR KR1020010007035A patent/KR100607117B1/ko active IP Right Grant
  • 2001-02-13 CN CNB011037563A patent/CN1195512C/zh not_active Expired - Lifetime
  • 2001-02-14 US US09/782,520 patent/US20010018060A1/en not_active Abandoned
  • 2001-02-15 JP JP2001038088A patent/JP2001261517A/ja active Pending

Patent Citations (19)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events